We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

172 hedge funds and large institutions have $835M invested in UroGen Pharma in 2026 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 52 increasing their positions, 47 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 25

11% more call options, than puts

Call options by funds: $4.26M | Put options by funds: $3.83M

11% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 47

3% more funds holding

Funds holding: 167 → 172 (+5)

1.97% more ownership

Funds ownership: 93.38% → 95.36% (+2%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

18% less capital invested

Capital invested by funds: $1.02B → $835M (-$189M)

Holders
172
Holders Change
+5
Holders Change %
+2.99%
% of All Funds
2.12%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
33
Increased
52
Reduced
47
Closed
25
Calls
$4.26M
Puts
$3.83M
Net Calls
+$423K
Net Calls Change
-$26.3M

Top Buyers

Rank Fund Capital Flow
1
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
+$52.5M
2
KCM
Kynam Capital Management
New Jersey
+$45.1M
3
OM
Opaleye Management
Massachusetts
+$23.3M
4
SCM
Soleus Capital Management
Connecticut
+$11.6M
5
FCM
Frontier Capital Management
Massachusetts
+$10.7M

Top Sellers

Rank Fund Capital Flow
1
PBA
Paradigm Biocapital Advisors
New York
-$55.5M
2
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
-$14.8M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$11.8M
4
Citadel Advisors
Citadel Advisors
Florida
-$9.42M
5
SCM
Superstring Capital Management
New York
-$6.64M
Name Holding Trade Value Shares
Change 		Change in
Stake
DFCM
176
Dark Forest Capital Management
Puerto Rico
– -$738K -31,516 Closed
Squarepoint
177
Squarepoint
New York
– -$535K -22,831 Closed
XT
178
XTX Topco
Cayman Islands
– -$527K -22,491 Closed
IIM
179
INTECH Investment Management
Florida
– -$520K -22,210 Closed
JF
180
Jump Financial
Illinois
– -$419K -17,900 Closed
CCM
181
Cinctive Capital Management
New York
– -$398K -16,991 Closed
OC
182
Oppenheimer & Co
New York
– -$397K -16,962 Closed
Marshall Wace
183
Marshall Wace
United Kingdom
– -$382K -16,300 Closed
WG
184
Winton Group
United Kingdom
– -$309K -13,188 Closed
CAM
185
Cresset Asset Management
Illinois
– -$263K -11,216 Closed
HSBC Holdings
186
HSBC Holdings
United Kingdom
– -$236K -10,316 Closed
BCI
187
Brinker Capital Investments
Pennsylvania
– -$211K -9,008 Closed
ProShare Advisors
188
ProShare Advisors
Maryland
– -$206K -8,812 Closed
SO
189
STRS Ohio
Ohio
– -$89K -3,800 Closed
AB
190
Amalgamated Bank
New York
– -$27K -1,159 Closed
ACM
191
Aster Capital Management
United Arab Emirates
– -$6.98K -298 Closed
QT
192
Quantbot Technologies
New York
– -$4.68K -200 Closed
Federated Hermes
193
Federated Hermes
Pennsylvania
– -$4.59K -196 Closed
Daiwa Securities Group
194
Daiwa Securities Group
Japan
– -$4K -160 Closed
US Bancorp
195
US Bancorp
Minnesota
– -$398 -17 Closed
AAP
196
Arax Advisory Partners
Colorado
– -$328 -14 Closed
C
197
Covestor
United Kingdom
– +$120 +6 New
4 5 6 7
8

URGN Hedge Fund Activity: Q1 2026 in Review

172 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q1 2026, worth a combined $835M — down 18% from $1.02B a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new URGN positions and 25 closed out — a net gain of 8 holders — while 52 added to existing stakes and 47 trimmed.

The largest buyer was Toronto Dominion Bank, opening a new position worth an estimated $52.5M. The largest seller was Paradigm Biocapital Advisors, cutting an estimated $55.5M.

  • 172 institutional investors held UroGen Pharma (URGN) as of Q1 2026, up from 167 in Q4 2025.
  • Funds reported $835M of UroGen Pharma stock for Q1 2026, down 18% quarter-over-quarter.
  • 33 funds opened new UroGen Pharma positions in Q1 2026 and 25 closed out, a net change of +8 holders.
  • The largest UroGen Pharma buyer in Q1 2026 was Toronto Dominion Bank, an estimated $52.5M added.
  • The largest UroGen Pharma seller in Q1 2026 was Paradigm Biocapital Advisors, an estimated $55.5M sold.

Based on aggregated 13F filings for Q1 2026.